Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Eli Lilly (NY: LLY)
111.74 USD  -0.08 (-0.07%)
Official Closing Price  /  Updated: 7:37 PM EDT, Jun 14, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 3,188,000
Open 112.13
Bid (Size) 111.54 (3)
Ask (Size) 112.48 (1)
Prev. Close 111.82
Today's Range 111.01 - 112.25
52wk Range 84.64 - 132.13
Shares Outstanding 1,085,430,420
Dividend Yield 2.02%
Performance
YTD
-2.73%
-2.73%
1 Month
-4.27%
-4.27%
3 Month
-10.78%
-10.78%
6 Month
+3.12%
+3.12%
1 Year
+28.61%
+28.61%
Top News
More News
Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress o
Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA)... Read More
from PR Newswire
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
Eli Lilly and Company (NYSE: LLY) announced today the company will present positive, five-year Phase 3 data for Taltz® (ixekizumab). Patients with moderate- to severe plaque psoriasis who continued to... Read More
from PR Newswire
More News
Read More
Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®
from PR Newswire
New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria
from PR Newswire
Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes
from PR Newswire
Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions
from PR Newswire
UPDATE 1-U.S. drugmakers file lawsuit against requiring drug prices in TV ads
category companyNews
from Reuters: Company News
Drugmakers file lawsuit to block rule requiring drug prices in TV ads
category LLY , Biotechnology , MRK , and 2 more.
from MarketWatch
U.S. drugmakers file lawsuit against rule requiring drug prices in TV ads
category companyNews
from Reuters: Company News
Terns Starts US Trial of Lead Drug, a NASH Candidate
from ChinaBio® Today
3 Top Diabetes Stocks to Watch in June
category Market News , ABT , SNY , and 2 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.